Authors: Emerson, DL Bendele, R Brown, E Chiang, SM Desjardins, JP Dihel, LC Gill, SC Hamilton, M LeRay, JD Moon-McDermott, L Moynihan, K Richardson, FC Tomkinson, B Luzzio, MJ Baccanari, D

Citation: Dl. Emerson et al., Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: A low-clearance liposomal formulation of lurtotecan, CLIN CANC R, 6(7), 2000, pp. 2903-2912

Authors: Drolet, DW Nelson, J Tucker, CE Zack, PM Nixon, K Bolin, R Judkins, MB Farmer, JA Wolf, JL Gill, SC Bendele, RA

Citation: Dw. Drolet et al., Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys, PHARM RES, 17(12), 2000, pp. 1503-1510

Authors: Tucker, CE Chen, LS Judkins, MB Farmer, JA Gill, SC Drolet, DW

Citation: Ce. Tucker et al., Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys, J CHROMAT B, 732(1), 1999, pp. 203-212

Authors: Floege, J Ostendorf, T Janssen, U Burg, M Radeke, HH Vargeese, C Gill, SC Green, LS Janjic, N

Citation: J. Floege et al., Novel approach to specific growth factor inhibition in vivo - Antagonism of platelet-derived growth factor in glomerulonephritis by aptamers, AM J PATH, 154(1), 1999, pp. 169-179